2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 82

Analysis of Intestinal Microbiome Profile of Patients with Established Rheumatoid Arthritis and Healthy Controls

Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 522

Analysis of Sequential Development of Pulmonary Lesions in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 651

Analysis of the Different Value of Magnetic Resonance Imaging Changes in the Sacroiliac Joints for a Diagnosis of Axial Spondyloarthritis As Judged By Rheumatologists and Radiologists

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 47

Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 480

Analyze Myositis with Ultrasound and Exercise (AMUSE) Kids- Initial Analysis of Longitudinal Data

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 649

Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 612

Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 4

Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 89

Anti-Nuclear Antibodies (ANA) and Air Pollution: Ultrafine Particles and Ozone

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 726

Anti-Retinoblastoma Protein Antibody Is Protective Against Lupus Nephritis

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 85

Antibodies to Citrullinated Protein Antigens (ACPAs) Induce Adipose Tissue Dysfunction Contributing to the Cardiovascular Disease Risk in Rheumatoid Arthritis. Modulation By Biological Dmards

Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 208

Antibodies to Citrullinated Protein Antigens Are Associated with Risk of Cardiovascular Disease in Community-Dwelling Women: The Multi-Ethnic Study of Atherosclerosis

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 114

Antifibrotic Regulation By Response Gene to Complement 32 Protein

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 376

Antisynthetase Syndrome: Prevalence of Serositis in Autoantibody Subsets

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 107

Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].